Sitbon O - Search Results

1

Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.

Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Sanchez O, et al. Among authors: sitbon o. Chest. 2006 Jul;130(1):182-9. doi: 10.1378/chest.130.1.182. Chest. 2006. PMID: 16840400

2

Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.

Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Humbert M, et al. Among authors: sitbon o. Am J Respir Crit Care Med. 1995 May;151(5):1628-31. doi: 10.1164/ajrccm.151.5.7735624. Am J Respir Crit Care Med. 1995. PMID: 7735624

3

[Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications].

Azarian R, Brenot F, Sitbon O, Parent F, Petitpretz P, Musset D, Grimon G, Dartevelle P, Simonneau G, Duroux P. Azarian R, et al. Among authors: sitbon o. Arch Mal Coeur Vaiss. 1994 Dec;87(12):1709-13. Arch Mal Coeur Vaiss. 1994. PMID: 7786111 Review. French.

4

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G. Sitbon O, et al. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):384-9. doi: 10.1164/ajrccm.151.2.7842196. Am J Respir Crit Care Med. 1995. PMID: 7842196 Clinical Trial.

5

Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension.

Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, Hervé P, Duroux P, Dinh-Xuan AT, Simonneau G. Raffy O, et al. Among authors: sitbon o. Circulation. 1996 Feb 1;93(3):484-8. doi: 10.1161/01.cir.93.3.484. Circulation. 1996. PMID: 8565165

6

Pulmonary vascular disorders in portal hypertension.

Hervé P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Hervé P, et al. Among authors: sitbon o. Eur Respir J. 1998 May;11(5):1153-66. doi: 10.1183/09031936.98.11051153. Eur Respir J. 1998. PMID: 9648972 Review.

7

Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).

Humbert M, Sanchez O, Fartoukh M, Jagot JL, Sitbon O, Simonneau G. Humbert M, et al. Among authors: sitbon o. Chest. 1998 Jul;114(1 Suppl):80S-82S. doi: 10.1378/chest.114.1_supplement.80s. Chest. 1998. PMID: 9676646 No abstract available.

8

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G. Sitbon O, et al. Eur Respir J. 1998 Aug;12(2):265-70. doi: 10.1183/09031936.98.12020265. Eur Respir J. 1998. PMID: 9727772

9

Primary pulmonary hypertension associated with the use of fenfluramine derivatives.

Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Hervé P. Simonneau G, et al. Among authors: sitbon o. Chest. 1998 Sep;114(3 Suppl):195S-199S. doi: 10.1378/chest.114.3_supplement.195s. Chest. 1998. PMID: 9741568 Review.

10

Treatment of pulmonary hypertension secondary to connective tissue diseases.

Sanchez O, Humbert M, Sitbon O, Simonneau G. Sanchez O, et al. Among authors: sitbon o. Thorax. 1999 Mar;54(3):273-7. doi: 10.1136/thx.54.3.273. Thorax. 1999. PMID: 10325906 Free PMC article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results